This Growing Concern Accounts For Nearly 500,000 Cancer Cases Each Year
A recent World Health Organization study shows that this growing problem is responsible for nearly a half-million cancer diagnoses each year.
Could This Company Follow in Dendreon's Footsteps?
Dendreon's fall from grace wasn't pretty, and another once highly regarded biotech may eventually follow suit.
Why Orexigen Therapeutics, Inc. Stock Rocketed 43% Higher in November
Orexigen Therapeutics is the best biotech stock in November after its earnings report highlights progress with its Contrave program overseas.